MX368767B - (5,6-dihidro)pirimido[4,5-e]indolizinas. - Google Patents

(5,6-dihidro)pirimido[4,5-e]indolizinas.

Info

Publication number
MX368767B
MX368767B MX2016012997A MX2016012997A MX368767B MX 368767 B MX368767 B MX 368767B MX 2016012997 A MX2016012997 A MX 2016012997A MX 2016012997 A MX2016012997 A MX 2016012997A MX 368767 B MX368767 B MX 368767B
Authority
MX
Mexico
Prior art keywords
indolizines
pyrimido
dihydro
cancer
aryl
Prior art date
Application number
MX2016012997A
Other languages
English (en)
Other versions
MX2016012997A (es
Inventor
Petrus Antonius De Man Adrianus
Christian Buijsman Rogier
Gerard STERRENBURG Jan
Cornelis Marinus UITDEHAAG Joost
Johannes Petrus DE WIT Joeri
Jenny Rudolf Zaman Guido
Original Assignee
Netherlands Translational Res Center B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Netherlands Translational Res Center B V filed Critical Netherlands Translational Res Center B V
Publication of MX2016012997A publication Critical patent/MX2016012997A/es
Publication of MX368767B publication Critical patent/MX368767B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a un compuesto de fórmula I: (ver Fórmula) Fórmula I, en donde, R1 y R2 se seleccionan independientemente entre el grupo que consiste de arilo de (C6-10) opcionalmente sustituido y grupos heteroarilo de (C1-5); los compuestos se pueden utilizar en composiciones farmacéuticas, en particular en el tratamiento del cáncer.
MX2016012997A 2014-04-07 2015-03-30 (5,6-dihidro)pirimido[4,5-e]indolizinas. MX368767B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14163734 2014-04-07
EP15153207 2015-01-30
PCT/EP2015/056839 WO2015155042A1 (en) 2014-04-07 2015-03-30 (5,6-dihydro)pyrimido[4,5-e]indolizines

Publications (2)

Publication Number Publication Date
MX2016012997A MX2016012997A (es) 2016-12-07
MX368767B true MX368767B (es) 2019-10-15

Family

ID=52774240

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016012997A MX368767B (es) 2014-04-07 2015-03-30 (5,6-dihidro)pirimido[4,5-e]indolizinas.

Country Status (16)

Country Link
US (2) US9856258B2 (es)
EP (1) EP3129374B1 (es)
JP (1) JP6518690B2 (es)
KR (1) KR102432420B1 (es)
CN (1) CN106132963B (es)
AU (1) AU2015243694B2 (es)
BR (1) BR112016022342B1 (es)
CA (1) CA2944610C (es)
DK (1) DK3129374T3 (es)
ES (1) ES2716165T3 (es)
HU (1) HUE043108T2 (es)
MX (1) MX368767B (es)
PL (1) PL3129374T3 (es)
PT (1) PT3129374T (es)
RU (1) RU2692479C2 (es)
WO (1) WO2015155042A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3283642T (pt) * 2015-04-17 2024-01-02 Crossfire Oncology Holding B V Biomarcadores de prognóstico para quimioterapia inibidora de ttk
EP3848373A1 (en) * 2016-02-19 2021-07-14 Phoenix Molecular Designs N-(1-((heterocyclyl)methyl)-1h-pyrazol-4-yl)-6-oxo-6,7,8,9- tetrahydropyrido[3',2':4,5]pyrrolo[l,2-a]pyrazine-2-carboxamide derivatives as p90 ribosomal s6 kinase (rsk) inhibitors for treating cancer
CN109311848B (zh) 2016-06-07 2022-02-01 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物
CN106551938B (zh) * 2016-11-26 2017-11-24 广东安诺药业股份有限公司 一种治疗非酒精性脂肪肝的药物及其应用
US10988466B2 (en) 2017-03-23 2021-04-27 Jacobio Pharmaceuticals Co., Ltd. Heterocyclic derivatives useful as SHP2 inhibitors
WO2023113479A1 (en) * 2021-12-15 2023-06-22 Sillajen, Inc. Pharmaceutical compositions comprising modified beta-cyclodextrins
WO2023113477A1 (en) * 2021-12-15 2023-06-22 Sillajen, Inc. Pharmaceutical combinations for use in the treatment of neoplastic diseases
WO2023113478A1 (en) * 2021-12-15 2023-06-22 Sillajen, Inc. Methods of treating neoplastic diseases
WO2023167549A1 (en) * 2022-03-04 2023-09-07 Sillajen, Inc. Pharmaceutical combinations for use in the treatment of neoplastic diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0401982A3 (en) * 2001-09-19 2012-09-28 Aventis Pharma Sa Indolizine derivates, process for their preparation and pharmaceutical compositions containing the compounds
KR101084871B1 (ko) 2003-05-22 2011-11-21 네르비아노 메디칼 사이언시스 에스.알.엘. 피라졸로-퀴나졸린 유도체, 그의 제조 방법 및 상기유도체의 키나제 저해제로서의 용도
JP5284973B2 (ja) 2006-11-28 2013-09-11 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 三環式インドールおよび(4,5−ジヒドロ)インドール
ES2572360T3 (es) 2008-06-26 2016-05-31 Servier Lab Pirazolo-quinazolinas como moduladores de la actividad de la proteína quinasa
WO2010111406A2 (en) 2009-03-24 2010-09-30 Myriad Pharmaceuticals, Inc. Compounds and therapeutic uses thereof
JP5801285B2 (ja) 2009-04-29 2015-10-28 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ Cdk阻害物質の塩
ES2553114T3 (es) 2009-07-29 2015-12-04 Nerviano Medical Sciences S.R.L. Sales de inhibidor de plk
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
WO2012080229A1 (en) 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment hyperproliferative disorders
JP5925809B2 (ja) * 2011-01-26 2016-05-25 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 三環系ピロロ誘導体、その調製方法およびそのキナーゼ阻害剤としての使用
JP6523267B2 (ja) 2013-06-24 2019-05-29 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung Fshrの調節剤としてのイミダゾール化合物及びその使用

Also Published As

Publication number Publication date
US20170096432A1 (en) 2017-04-06
WO2015155042A1 (en) 2015-10-15
MX2016012997A (es) 2016-12-07
CN106132963B (zh) 2019-08-06
AU2015243694B2 (en) 2019-01-17
JP2017510595A (ja) 2017-04-13
EP3129374B1 (en) 2018-12-19
RU2016141405A (ru) 2018-05-07
CA2944610C (en) 2024-01-09
AU2015243694A1 (en) 2016-11-03
PT3129374T (pt) 2019-03-25
PL3129374T3 (pl) 2019-07-31
KR20170013866A (ko) 2017-02-07
EP3129374A1 (en) 2017-02-15
RU2016141405A3 (es) 2018-10-02
HUE043108T2 (hu) 2019-07-29
USRE48974E1 (en) 2022-03-15
RU2692479C2 (ru) 2019-06-25
JP6518690B2 (ja) 2019-05-22
CA2944610A1 (en) 2015-10-15
BR112016022342A8 (pt) 2021-07-20
CN106132963A (zh) 2016-11-16
BR112016022342B1 (pt) 2022-10-04
BR112016022342A2 (pt) 2017-08-15
US9856258B2 (en) 2018-01-02
DK3129374T3 (en) 2019-04-08
ES2716165T3 (es) 2019-06-10
KR102432420B1 (ko) 2022-08-17

Similar Documents

Publication Publication Date Title
MX2016012997A (es) (5,6-dihidro)pirimido[4,5-e]indolizinas.
PH12017500408B1 (en) Heteroaryl compounds as btk inhibitors and uses thereof
PH12018502535A1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
EA033266B1 (ru) Гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их
CL2016002735A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
PH12018500987A1 (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
MY190243A (en) Hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them
GEP20186887B (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
JO3195B1 (ar) مشتقات أندوليزين جديدة, وطريقة تحضيرهم والتركيبات الصيدلانية التي تحتوي عليهم لعلاج السرطان
EP3597649B8 (en) Compositions containing substituted [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compounds as pde2 inhibitors
MD4820C1 (ro) Compuşi dihidroizochinolinonici substituiţi
MX2015014234A (es) Derivados 2-aminopirido-[4,3-d]pirimidin-5-ona y su uso como inhibidores de wee-1.
MX2016006432A (es) Tetrahidro-benzodiazepinonas.
MY191628A (en) Novel triazolo[4,5-d]pyrimidine derivatives
JO3310B1 (ar) مشتقات إندوليزين جديدة وطريقة لإنتاجها وتركيبات صيدلانية تحتوي عليها
TN2015000262A1 (en) Pyrimido [4,5-b]quinoline-4,5 (3h,10h)-diones as nonsense mutation suppressors
MX2016009251A (es) Derivados de 7-oxo-1, 6-diazabiciclo [3.2.1] octano y su uso como agentes antibacterianos.
TW201613864A (en) Novel compounds
AU2015352440B2 (en) Compounds
HK1247203A1 (zh) 取代的咪唑並[1,2-α]吡啶-2-基胺化合物及其藥物組合物和使用方法
CY1120602T1 (el) [1,2,4]τριαζολο[4,3-β]πυριδαζινες για χρηση στη θεραπευτικη αντιμετωπιση πολλαπλασιαστικων ασθενειων
TN2018000090A1 (en) New imidazo[4,5-b]pyridine derivatives as dual dyrk1/clk1 inhibitors
PH12017500342A1 (en) 7 - (morpholinyl) -2- (n-piperazinyl) methyl thieno [2,3-c] pyridine derivatives as anticancer drugs
PH12016501997A1 (en) Cycloalkyl-linked diheterocycle derivatives
MX2017006051A (es) Derivados de 2,3-dihidro-tiazolo[3,2-a]piridin-5-ona, intermediarios de los mismos, y su uso como agentes antibacterianos.

Legal Events

Date Code Title Description
FG Grant or registration